Bharat Oza, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 656 S Broadway St, New Philadelphia, OH 44663 Phone: 330-308-8811 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.
Boehringer Ingelheim will announce positive results from the landmark RE-COVERâ„¢ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVERâ„¢ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company's lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
A collaborative team of researchers spearheaded by Dennis Carson M.D., professor of medicine and director of the Rebecca and John Moores UCSD Cancer Center at the University of California, San Diego (UCSD) has identified a potent new anti-cancer drug isolated from a toxic blue-green algae found in the South Pacific.
› Verified 8 days ago